Trial · NCT01862991
Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services
NCT01862991, Not applicable, Completed, Stanford University; results first posted 2017-06-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services. Trials, record NCT01862991. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01862991
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services
- NCT number
- NCT01862991
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 80 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Legally Induced Abortion Without Mention of Complication
- Interventions
- Hygroscopic cervical dilators, Misoprostol, Intra-amniotic digoxin, Mifepristone
- First posted
- 2013-05-27
- Last updated
- 2024-02-14
- Results first posted
- 2017-06-01
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Procedure Time | Intraoperative Time, Collected immediately within procedure | Measured as time from speculum insertion to removal |
| Secondary | Adverse Events | Intraoperatively and 2 weeks post operatively | Uterine perforation |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Procedure Time | Intraoperative Time, Collected immediately within procedure | minutes | MEDIAN | |
| SECONDARY | Adverse Events | Intraoperatively and 2 weeks post operatively | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Procedure Time | Dilapan-Placebo | 13 | Full Range 6 to 26 | minutes | |
| Procedure Time | Dilapan-Mifepristone | 12 | Full Range 7 to 25 | minutes | |
| Procedure Time | Mifepristone | 18.5 | Full Range 8 to 52 | minutes | |
| Adverse Events | Dilapan-Placebo | 0 | Participants | ||
| Adverse Events | Dilapan-Mifepristone | 1 | Participants | ||
| Adverse Events | Mifepristone | 2 | Participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dilapan-Placebo | 24 | |
| Overall Study | STARTED | Dilapan-Mifepristone | 28 | |
| Overall Study | STARTED | Mifepristone | 28 | |
| Overall Study | COMPLETED | Dilapan-Placebo | 21 | |
| Overall Study | COMPLETED | Dilapan-Mifepristone | 27 | |
| Overall Study | COMPLETED | Mifepristone | 27 | |
| Overall Study | NOT COMPLETED | Dilapan-Placebo | 3 | |
| Overall Study | NOT COMPLETED | Dilapan-Mifepristone | 1 | |
| Overall Study | NOT COMPLETED | Mifepristone | 1 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cervical Laceration | Reproductive system and breast disorders | Dilapan-Placebo | 1 | 21 | 1 |
| other | Cervical Laceration | Reproductive system and breast disorders | Dilapan-Mifepristone | 0 | 27 | 0 |
| other | Cervical Laceration | Reproductive system and breast disorders | Mifepristone | 5 | 27 | 5 |
| serious | Uterine Perforation | Reproductive system and breast disorders | Dilapan-Placebo | 0 | 21 | 0 |
| serious | Uterine Perforation | Reproductive system and breast disorders | Dilapan-Mifepristone | 1 | 27 | 1 |
| serious | Uterine Perforation | Reproductive system and breast disorders | Mifepristone | 2 | 27 | 2 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dilapan-Placebo | ||
| Total, all-cause mortality | Dilapan-Mifepristone | ||
| Total, all-cause mortality | Mifepristone | ||
| Total, other adverse events | Dilapan-Placebo | 1 | 21 |
| Total, other adverse events | Dilapan-Mifepristone | 0 | 27 |
| Total, other adverse events | Mifepristone | 5 | 27 |
| Total, serious adverse events | Dilapan-Placebo | 0 | 21 |
| Total, serious adverse events | Dilapan-Mifepristone | 1 | 27 |
| Total, serious adverse events | Mifepristone | 2 | 27 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01862991
GET https://conductscience.org/api/trials/v1/NCT01862991/registered